Security of CIMAvax-EGF(R) vaccine for the treatment of patients with NSCLC in advanced stages. Effectiveness exploration according to baseline concentrations of EGF. phase IV

Trial Profile

Security of CIMAvax-EGF(R) vaccine for the treatment of patients with NSCLC in advanced stages. Effectiveness exploration according to baseline concentrations of EGF. phase IV

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs BV NSCLC 001 (Primary) ; Cyclophosphamide
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top